CDK4 and breast carcinoma: While the combination of CDK4/6 inhibitors and endocrine therapy prolongs progression-free survival and overall survival among patients with metastatic HR + breast cancer and more recently has demonstrated clinical benefit in patients with HR + N + high risk early breast cancer, the potential benefit of these combinations in the neoadjuvant setting remains unclear [18–21].